Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865146 | 0.88 | PTGS2 (0.69) | PTGS2SMN1; SMN2CHRNA7PTGS1MALT1 | |
| SCHEMBL3866686 | 0.86 | SMPD1 (0.56) | PTGS2SMN1; SMN2CHRNA7MALT1NFKB1 | |
| SCHEMBL3869717 | 0.85 | CHRNA7 (0.48) | PTGS2CHRNA7PTGS1CYP2C9EPHX2 | |
| SCHEMBL3873182 | 0.85 | SMPD1 (0.58) | PTGS2SMN1; SMN2MALT1NFKB1NFKB2 | |
| SCHEMBL3863671 | 0.85 | SMN1; SMN2 (0.69) | PTGS2SMN1; SMN2CHRNA7MALT1NFKB1 | |
| SCHEMBL3863714 | 0.85 | RPA1 (0.60) | PTGS2SMN1; SMN2CHRNA7PTGS1MALT1 | |
| SCHEMBL3876516 | 0.85 | RPA1 (0.56) | PTGS2SMN1; SMN2FAAHMALT1 | |
| SCHEMBL3869946 | 0.84 | PTGS2 (0.64) | PTGS2SMN1; SMN2CHRNA7PTGS1CYP2C9 | |
| SCHEMBL3870127 | 0.83 | RPA1 (0.52) | PTGS2SMN1; SMN2 | |
| SCHEMBL3865209 | 0.80 | ILK (0.52) | PTGS2CHRNA7PTGS1CYP2C9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7442802-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-7087630-B2 | Cyclooxygenase 2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885SMN1; SMN2 2470/4885CHRNA7 4626/4885 |
| US-20060194861-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885SMN1; SMN2 2470/4885CHRNA7 4626/4885 |
| US-20090005350-A1 | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885SMN1; SMN2 2470/4885CHRNA7 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.